Efficacy
tumor
DISEASE, MINOR, REGRESSIONS, TUMOR
Although minor tumor regressions were seen in four patients, no RECIST‐defined partial responses were observed (Figure Response and outcome data. Waterfall plot (A) and swimmers plot (B) for the 10 patients treated with palbociclib and ganitumab.The median duration of therapy was 2.5 months (range 0.9–10.8) and five patients had stable disease as best response (Figure Progression‐free survival and overall survival. Progression‐free survival from date of enrollment (red dashed line) and overall survival from date of enrollment (blue solid line) for the 10 patients treated with palbociclib and ganitumab. Tick marks indicate patients who were censored.